OVATION Pharmaceuticals, Inc. (6630680) and Cardinal Health, Inc. (NYSE:CAH) have recently received a USFDA approval letter for Cardinal Health's new sterile facility in North Raleigh, N.C. for the manufacture of Panhematin® (hemin for injection), OVATION Pharma, Inc.’s biologic therapy for the treatment of a rare genetic disorder called acute porphyria.
Panhematin is the first USFDA-approved drug for commercial production at the new facility and also the only FDA-approved therapy for acute porphyria.
OVATION Pharma, Inc.’s manufacturing relationship with Cardinal Health, Inc. is part of the company’s ongoing global commitment to ensure that patients suffering from severe illnesses have access to life-saving therapies.
Acute porphyria is a rare genetic disorder caused by deficiencies of specific enzymes in the heme biosynthetic pathway, that if left untreated may lead to long-term or permanent paralysis, coma or even death.
According to Joseph Bloomer, M.D., Professor of Medicine and Director of the University of Alabama Liver Center:
"Acute porphyria is a very rare condition and few companies would be willing to invest in the area.
The support from Ovation and Cardinal Health is critical to ensuring product supply, as Panhematin is the mainstay of treatment."
The USFDA has designated acute porphyria as an orphan disease.
Read more at OVATION Pharmaceuticals, Inc.
Comment Preview